The clinical trials in leukemia are planned for KO-539 and SNDX-5613 which target the mixed lineage leukemia (MLL) transcription factor and inhibit its binding to menin which prevents this fusion protein from activating genes driving leukemia. This evidence concerns the gene MEN1 and leukemia.